About: Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Creator	Liu, Enmei Luo, Zhengxiu Yu, Yang Liao, Jing Wang, Xia Zhou, Qi Chen, Yaolong Li, Weiguo Lee, Myeong Ahn, Hyeong Fukuoka, Toshio Li, Qubei Lu, Shuya Luo, Xufei Ma, Yanfang Shi, Qianling Wang, Zijun Xun, Yangqin Yang, Kehu Qubei, ;
source	MedRxiv
abstract	Background: The COVID-19 outbreak presents a new, life-threatening disease. Our aim was to assess the potential effectiveness and safety of antiviral agents for COVID-19 in children. Methods: Electronic databases from their inception to March, 31 2020 were searched for randomized controlled trials, clinical controlled trials and cohort studies of interventions with antiviral agents for children (less than 18 years of age) with COVID-19. Results: A total of 23 studies of indirect evidence with 6008 patients were included. The risks of bias in all studies were moderate to high in general. The effectiveness and safety of antiviral agents for children with COVID-19 is uncertain: For adults with COVID-19, lopinavir/ritonavir had no effect on mortality (risk ratio [RR]= 0.77, 95% confidence interval [CI] 0.45 to 1.30) and probability of negative PCR test (RR=0.98, 95 CI% 0.82 to 1.18). Arbidol had no benefit on probability of negative PCR test (RR=1.27, 95% CI 0.93 to 1.73). Hydroxychloroquine was not associated with increasing the probability of negative PCR result (RR=0.93, 95% CI 0.73 to 1.18). For adults with SARS, interferon was associated with reduced corticosteroid dose (weighted mean difference [WMD]=-0.14 g, 95% CI -0.21 to -0.07) but had no effect on mortality (RR=0.72, 95% CI 0.28 to 1.88); ribavirin did not reduce mortality (RR=0.68, 95% CI % 0.43 to 1.06) and was associated with high risk of severe adverse reactions; and oseltamivir had no effect on mortality (RR=0.87, 95% CI 0.55 to 1.38). Ribavirin combined with interferon was also not effective in adults with MERS and associated with adverse reactions. Conclusions: There is no evidence showing the effectiveness of antiviral agents for children with COVID-19, and the clinical efficacy of existing antiviral agents is still uncertain. We do not suggest clinical routine use of antivirals for COVID-19 in children, with the exception of clinical trials. Keywords: Antiviral agents; children; COVID-19; meta-analysis; rapid review.
has issue date	2020-04-17(xsd:dateTime)
bibo:doi	10.1101/2020.04.13.20064436
has license	medrxiv
sha1sum (hex)	cf33527c910d28d20e0c691c98e11d3679f30b7d
schema:url	https://doi.org/10.1101/2020.04.13.20064436
resource representing a document's title	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
resource representing a document's body	covid:cf33527c910d28d20e0c691c98e11d3679f30b7d#body_text
is schema:about of	named entity 'assess' named entity 'NEW' named entity 'OUR' named entity 'COVID-19' named entity 'Running' named entity 'Title' named entity 'COVID' named entity 'antiviral agents' named entity 'Coronavirus Disease 2019' named entity 'COVID-19' named entity 'Title Page' named entity 'HCQ' named entity 'medRxiv' named entity 'remdesivir' named entity 'preprint' named entity 'IFN-β' named entity 'medRxiv' named entity 'WMD' named entity 'research results' named entity 'preprint' named entity 'adverse reactions' named entity 'medRxiv' named entity 'HCQ' named entity 'preprint' named entity 'MeSH' named entity 'placebo' named entity 'peer-reviewed' named entity 'medRxiv' named entity 'high-quality clinical research' named entity 'remission' named entity 'preprint' named entity 'cohort studies' named entity 'confounding' named entity 'medRxiv' named entity 'preprint' named entity 'preprint' named entity 'evidence-based' named entity 'antiviral' named entity 'preprint' named entity 'allocation concealment' named entity 'arbidol' named entity 'preprint' named entity 'COVID' named entity 'peer-reviewed' named entity 'preprint' named entity 'medRxiv' named entity 'oseltamivir' named entity 'crude death rate' named entity 'preprint' named entity 'Severe Acute Respiratory Syndrome' named entity 'health workers' named entity '95% CI' named entity '1.06' named entity 'middle-income' named entity 'statistically significant' named entity 'preprint' named entity 'medRxiv' named entity 'Kaletra' named entity 'make decisions' named entity 'medRxiv' named entity '2019-nCoV' named entity 'coronavirus' named entity 'COVID-19' named entity 'medRxiv' named entity 'COVID-19' named entity 'medRxiv'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software